Navigation Links
Pharmos Corporation Reports 2007 Third Quarter Results

as a treatment for pain in patients with knee osteoarthritis. The Company's core proprietary technology platform focuses on discovery and development of synthetic cannabinoid compounds, especially CB2 receptor-selective (CB2-selective) agonists. PRS-639,058, the leading CB2-selective agonist, has demonstrated promising preclinical data in neuropathic pain. Various other CB2-selective compounds from Pharmos' pipeline are in preclinical studies targeting pain, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and other disorders.

Safe Harbor Statement

Statements made in this press release related to the business outlook and future financial performance of Pharmos, to the prospective market penetration of its drug products, to the development and commercialization of its pipeline products and to its expectations in connection with any future event, condition, performance or other matter, are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos' filings with the Securities and Exchange Commission could affect such results.



Consolidated Statements of Operations

Three months ended Nine months ended

September 30, September 30,

2007 2006 2007 2006


Research and


gross $2,711,774 $2,338,392 $9,285,543 $6,587,480

Grants (238,123) (415,203) (769,072) (1,083,464)

Research and

development, net

of grants 2,473,651 1

SOURCE Pharmos Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
11. Sonic Foundry reports GAAP loss as Q2 revenues rise
Post Your Comments:
(Date:10/8/2015)... ... 08, 2015 , ... Cystic fibrosis (CF) is a genetic ... and results in dysfunction of the lungs and the gastrointestinal (GI) tract. In ... is very difficult to clear, blocks the airways and the glands, and creates ...
(Date:10/7/2015)... Worth, Texas (PRWEB) , ... October 07, 2015 ... ... Cell Institute ( ) will present a public educational seminar on the ... on Saturday, October 10th from 1:00 pm – 3:00 pm at the Hilton ...
(Date:10/7/2015)... Oct. 7, 2015  October is National Liver Awareness Month ... to donating a portion of its October profits to ... practices. ... variety of ways; whether it is by providing the ... with researchers in different disease and investigation areas, or ...
(Date:10/7/2015)... ... October 07, 2015 , ... ReliantHeart, ... S. Russel Craig of Spectral Platforms, and Michael Ward of Wrenward Medical Systems ... and consulting experience. Currently he is Executive Vice President of Strategic Relationships and ...
Breaking Biology Technology:
... WEST LAFAYETTE, Ind. - A team of Purdue University ... that has successfully created ultrapure material that captures new ... quantum computing. The material, gallium arsenide, is used ... the laws of single-particle physics, but instead are governed ...
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today reported ... For the second quarter ended June 30, 2011, Sangamo reported ... share, compared to a net loss of $3.9  million, or ... of June 30, 2011, the company had cash, cash equivalents ...
... NEW YORK, July 27, 2011 Keryx Biopharmaceuticals, Inc. ... patient enrollment in its Phase 3 registration trial of ... cancer.  This Phase 3 trial, with over 430 randomized ... Assessment (SPA) with the Food and Drug Administration (FDA) ...
Cached Biology Technology:
(Date:9/10/2015)... -- Report Details Emerging Biological Drugs ... Revenue Prospects to Help You Stay Ahead ... drug classes? Get the latest technological and commercial ... data and industry knowledge, benefitting your influence. And ... sales predictions. Visiongain,s new study reveals what,s ...
(Date:9/10/2015)... ATLANTA , Sept. 10, 2015 ... Cleveland Clinic Wellness to create an interactive, image-based ... self-service health and wellness kiosk.  The unique assessment ... Age"— a number that suggests an individual,s biological ... biometric values as measured by the kiosk. ...
(Date:9/9/2015)... Columbia , Sept. 9, 2015  NuData ... organizational and solution-based milestones, furthering the company,s commitment ... of online fraud. NuData Security,s online ... enhancing the company,s growth cycle. The product combines ... to determine good user behavior from fraudulent behavior, ...
Breaking Biology News(10 mins):
... June 30, 2011 Jerusalem, Israel The Israeli ... industrial R&D and innovation, has released new data from ... and strategic consulting firm Applied Economics Ltd., to mark ... anniversary. The study presents the proven impact of ...
... many plastic cards currently crowd your wallet, one day ... The Department of Homeland Security(DHS),s Science and Technology Directorate ... a portable device used for measuring exposure to ionizing ... unlikely event of a nuclear accident or dirty bomb. ...
... Calif. Susan R. Wessler , who holds ... distinguished professor of genetics in the Department of ... California, Riverside, has been named the recipient of the ... ) 2012 Excellence in Science Award. The award ...
Cached Biology News:
Collected from sexually mature mice....
Collected from 8-12 week-old New Zealand or Californian rabbits.,Supplied in lyophilized form....
Biology Products: